Pozelimab
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Geographic Atrophy (GA)
Conditions
Geographic Atrophy (GA)
Trial Timeline
Jan 19, 2026 → Jul 3, 2028
NCT ID
NCT07230834About Pozelimab
Pozelimab is a phase 1 stage product being developed by Regeneron Pharmaceuticals for Geographic Atrophy (GA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07230834. Target conditions include Geographic Atrophy (GA).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05232110 | Pre-clinical | Completed |
| NCT06003881 | Pre-clinical | Completed |
| NCT07142343 | Approved | Recruiting |
| NCT07230834 | Phase 1 | Recruiting |
| NCT04491838 | Phase 1 | Completed |
| NCT04209634 | Phase 2/3 | Completed |
Competing Products
20 competing products in Geographic Atrophy (GA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| avacincaptad pegol | Astellas Pharma | Phase 3 | 77 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2/3 | 65 |
| avacincaptad pegol | Astellas Pharma | Approved | 85 |
| Avacincaptad pegol (ACP) | Astellas Pharma | Pre-clinical | 23 |
| Avacincaptad Pegol + Sham | Astellas Pharma | Phase 3 | 77 |
| ABBV-6628 + SYFOVRE | AbbVie | Phase 1/2 | 41 |
| FWY003 + Placebo | Novartis | Phase 2 | 52 |
| CLG561 + LFG316 + Sham injection | Novartis | Phase 2 | 52 |
| LFG316 + Sham + LFG316 Lower dose | Novartis | Phase 2 | 52 |
| Lampalizumab | Roche | Phase 3 | 77 |
| Lampalizumab | Roche | Phase 3 | 77 |
| Lampalizumab | Roche | Phase 3 | 77 |
| RO7669330 + Syfovre™ + Izervay™ | Roche | Phase 1 | 33 |
| RO7303359 | Roche | Phase 1 | 33 |
| SAR446597 + Sham Comparator | Sanofi | Phase 1/2 | 40 |
| IONIS-FB-Lrx + Placebo (sterline saline 0.9%) | Ionis Pharmaceuticals | Phase 2 | 49 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 74 |
| Pegcetacoplan | Apellis Pharmaceuticals | Pre-clinical | 18 |
| APL-2 + APL-2 | Apellis Pharmaceuticals | Phase 3 | 72 |
| APL-2, Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |